TY - JOUR T1 - Development, testing and validation of a SARS-CoV-2 multiplex panel for detection of the five major variants of concern on a portable PCR platform JF - medRxiv DO - 10.1101/2022.08.02.22277351 SP - 2022.08.02.22277351 AU - Bryce J Stanhope AU - Brittany Peterson AU - Brittany Knight AU - Ray Nobles Decadiz AU - Roger Pan AU - Phillip Davis AU - Anne Fraser AU - Manunya Nuth AU - Jesse vanWestrienen AU - Erik Wendlandt AU - Bruce Goodwin AU - Chris Myers AU - Jennifer Stone AU - Shanmuga Sozhamannan Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/08/02/2022.08.02.22277351.abstract N2 - Many SARS-CoV-2 variants have emerged during the course of the COVID-19 pandemic. These variants have acquired mutations conferring phenotypes such as increased transmissibility or virulence, or causing diagnostic, therapeutic, or immune escape. Detection of Alpha and the majority of Omicron sublineages by PCR relied on the so-called S gene target failure due to the deletion of six nucleotides coding for amino acids 69-70 in the spike (S) protein. Detection of hallmark mutations in other variants present in samples relied on whole genome sequencing. However, whole genome sequencing as a diagnostic tool is still in its infancy due to geographic inequities in sequencing capabilities, higher cost compared to other molecular assays, longer turnaround time from sample to result, and technical challenges associated with producing complete genome sequences from samples that have low viral load and/or high background. Hence, there is a need for rapid genotyping assays. In order to rapidly generate information on the presence of a variant in a given sample, we have created a panel of four triplex RT-qPCR assays targeting 12 mutations to detect and differentiate all five variants of concern: Alpha, Beta, Gamma, Delta and Omicron. We also developed an expanded pentaplex assay that can reliably distinguish among the major sublineages (BA.1-BA.5) of Omicron. In silico, analytical and clinical testing of the variant panel indicate that the assays overall exhibit high sensitivity and specificity. This variant panel can be used as a Research Use Only screening tool for triaging SARS-CoV-2 positive samples prior to whole genome sequencing.Competing Interest StatementCompeting interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: no support from any organization for the submitted work other than those described in the Funding section; no financial relationships with any organizations that might have an interest in the submitted work in the previous three years other than the reported author affiliations (which include employees of Biomeme, Inc.); no other relationships or activities that could appear to have influenced the submitted work.Funding StatementFunding for this study was provided by the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency (DHA) COVID funding initiative for this effort: Development of a Biomeme Variant Panel under the Contract (FA807518D0017) with MRIGlobal, and a Subcontract (867-111084-20) between MRIGlobal and Biomeme, Inc. Work performed by Naval Health Research Center (NHRC) was also funded via DBPAO contract (N2016).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of the Naval Health Research Center waived ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript and supplemental files. Any additional data are available upon reasonable request to the authors. ER -